GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohit Oyj (OHEL:BIOBV) » Definitions » EV-to-EBITDA

Biohit Oyj (OHEL:BIOBV) EV-to-EBITDA : 11.86 (As of May. 14, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biohit Oyj EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biohit Oyj's enterprise value is €23.81 Mil. Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €2.01 Mil. Therefore, Biohit Oyj's EV-to-EBITDA for today is 11.86.

The historical rank and industry rank for Biohit Oyj's EV-to-EBITDA or its related term are showing as below:

OHEL:BIOBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -209.74   Med: -15.47   Max: 67.58
Current: 11.86

During the past 13 years, the highest EV-to-EBITDA of Biohit Oyj was 67.58. The lowest was -209.74. And the median was -15.47.

OHEL:BIOBV's EV-to-EBITDA is ranked worse than
55.94% of 463 companies
in the Biotechnology industry
Industry Median: 9.32 vs OHEL:BIOBV: 11.86

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Biohit Oyj's stock price is €1.98. Biohit Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.120. Therefore, Biohit Oyj's PE Ratio for today is 16.50.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biohit Oyj EV-to-EBITDA Historical Data

The historical data trend for Biohit Oyj's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohit Oyj EV-to-EBITDA Chart

Biohit Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.56 -25.29 32.20 11.40 11.14

Biohit Oyj Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.20 - 11.40 - 11.14

Competitive Comparison of Biohit Oyj's EV-to-EBITDA

For the Biotechnology subindustry, Biohit Oyj's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohit Oyj's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohit Oyj's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biohit Oyj's EV-to-EBITDA falls into.



Biohit Oyj EV-to-EBITDA Calculation

Biohit Oyj's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=23.813/2.008
=11.86

Biohit Oyj's current Enterprise Value is €23.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €2.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohit Oyj  (OHEL:BIOBV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biohit Oyj's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.98/0.120
=16.50

Biohit Oyj's share price for today is €1.98.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biohit Oyj EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biohit Oyj's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohit Oyj (OHEL:BIOBV) Business Description

Traded in Other Exchanges
N/A
Address
Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies and service laboratory operations.

Biohit Oyj (OHEL:BIOBV) Headlines

No Headlines